Innoviva

INVA NASDAQ
11.48
+0.26
+2.32%
After Hours: 11.48 0 0.00% 17:00 08/16 EDT
Open
11.26
Prev Close
11.22
High
11.51
Low
11.16
Volume
407.29K
Avg Vol (3M)
778.88K
52 Week High
20.54
52 Week Low
10.93
% Turnover
0.40%
Market Cap
1.16B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Innoviva INVA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
MORE >

Recently

Name
Price
%Change